AYMROXA
Live / Applied — First extension granted (statement of use) (as of 05 Mar 2026)
What this means for you
Not registered yet, but its 12 Sept 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98747397
- Mark type
- Stylized text
- Filed
- 12 Sept 2024
- Published for opposition
- 22 Jul 2025
- Attorney of record
- Elsa D. Lemoine
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; Pharmaceutical preparations for the treatment of the respiratory system; Pharmaceutical preparations for the treatment of the gastrointestinal disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic dermatitis, autoimmune diseases and disorders; Pharmaceutical preparations for the treatment of asthma and other breathing disorders
Owner
- Amgen Inc., Thousand Oaks, CA, US
- Amgen Inc., Thousand Oaks, CA, US
Prosecution history
- 06 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Mar 2026 — SOU EXTENSION 1 GRANTED
- 05 Mar 2026 — SOU EXTENSION 1 FILED
- 05 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 16 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 22 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 22 Jul 2025 — PUBLISHED FOR OPPOSITION
- 16 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Jun 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Jun 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Jun 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Apr 2025 — ASSIGNED TO LIE
- 18 Dec 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 18 Dec 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED